Infections

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

All Drugs and Chemicals

Resiquimod

Immunomodulating Agents

Immunologic Factors

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.

A second purpose is to evaluate the safety of the drug.

Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults

Graceway Pharmaceuticals, LLC

The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.

A second purpose is to evaluate the safety of the drug.

Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects

A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects

Three day application of 0.05% PEP005 Topical Gel to one or two common warts located on the hand.

PEP005

Angela Smith

Verruca vulgaris, otherwise known as the common wart, is caused by the human papillomavirus (HPV). Common warts are generally located on the hands and feet, but can also occur elsewhere (e.g., any areas of frequent contact). Common warts have a characteristic cauliflower-like surface, are typically slightly raised above the surrounding skin and are generally diagnosed by visual inspection.The treatment of warts poses a therapeutic challenge for physicians. No single therapy has been proven effective at achieving complete remission in every patient.This study will aim to evaluate an up-to a three-day course of therapy with 0.05% PEP005 Topical Gel.

The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)

A Phase I, Single-Centre, Open-Label, Fixed-Dose Study of the Safety and Efficacy of up- to Three-Days Application of 0.05% PEP005 Topical Gel in the Treatment of Patients With Common Wart(s) (Verruca[e] Vulgaris) on the Dorsal Hand

Peplin

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults	NCT00114920	Warts	Resiquimod	18 Years -	Graceway Pharmaceuticals, LLC
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects	NCT00116675	Warts	Resiquimod	3 Years - 11 Years	Graceway Pharmaceuticals, LLC
The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)	NCT00546611	Warts	PEP005	18 Years -	Peplin
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults	NCT00114920	Warts	Resiquimod	18 Years -	Graceway Pharmaceuticals, LLC

Spots Global Cancer Trial Database for common wart(s)